The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Emily Bodnar, an analyst at H.C. Wainwright, raised her price target for Purple Biotech Ltd. (NASDAQ:PPBT) from $33 to $34 ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

Investors' deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approval and M&A Biotech is one of the U.S. stock market's most unloved sectors. But several ...

3SBio's shares surged 32% to 19.18 Hong Kong dollars, equivalent to US$2.45, on Tuesday after the Chinese company said it would receive an upfront payment of US$1.25 billion and potential milestone ...

Biotech stocks lagged the broader market in 2023 and 2024, and the SDPR S&P Biotech ETF (NYSE: XBI) is trading at the same level as in 2017. While biotech stocks soared during the COVID-19 ...